Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...

The Enbrel biosimilar, which is branded as Erelzi ... that could be spent on newer drugs as well as widening access to biologic medicines. As these medicines are produced in cells instead ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN stock is a Hold.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The company offers medicines and vaccines in various therapeutic areas, including: Cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands Biologics, small ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

It didn’t achieve that with Remicade and Enbrel, which were the first two anti-TNF biologics to face competition. In fact, Remicade took 28 months to reach the 80% target, and after 12 months ...

The absolute number of new biologic drug approvals in any given ... including Amgen's Enbrel (etanercept), Abbott's Humira and Remicade, marketed in the US by J&J and in Europe by Merck of ...

Q. Is there any cure for psoriasis? A. There’s no cure for psoriasis yet, but there are many ways to get relief from the symptoms of this troublesome disease. Psoriasis is one of the most ...

Since the turn of the last century, biological research has been identifying ... and two such products, Ontak and Enbrel (see Table 1) have been recently approved. Although protein engineering ...